SCHEMBL5385244

SCHEMBL5385244

Cc1cc(C)c(S(=O)(=O)c2ncn(C(=O)N(C)C(C)C)n2)c(C)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.48
ALDH1A1 P00352 4/20 0.38
MAPT P10636 3/20 0.38
KDM4E B2RXH2 1/20 0.36
KMT2A Q03164 1/20 0.36
RAPGEF4 Q8WZA2 5/20 0.35
NPSR1 Q6W5P4 1/20 0.34
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
MMP1 P03956 1/20 0.33
MMP2 P08253 1/20 0.33
MMP9 P14780 1/20 0.33
MMP8 P22894 1/20 0.33
MMP13 P45452 1/20 0.33
MAPK1 P28482 1/20 0.32
GLA P06280 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
PKM P14618 1/20 0.31
F2 P00734 1/20 0.31
PRSS1 P07477 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5376972 0.90 ALDH1A1 (0.45) DPP4ALDH1A1MAPTKDM4EKMT2A
SCHEMBL5381790 0.86 ALDH1A1 (0.40) DPP4ALDH1A1MAPTKDM4EKMT2A
Cafenstrole SCHEMBL54625 0.85 KMT2A (0.49) DPP4ALDH1A1MAPTKDM4EKMT2A
SCHEMBL5378985 0.83 ALDH1A1 (0.38) DPP4ALDH1A1MAPTKDM4EKMT2A
SCHEMBL5381321 0.82 ALDH1A1 (0.42) ALDH1A1MAPTKDM4EKMT2ARAPGEF4
SCHEMBL8859187 0.81 F2 (0.40) ALDH1A1MAPTKDM4EKMT2ARAPGEF4
SCHEMBL7316902 0.75 ALDH1A1 (0.37) ALDH1A1MAPTKDM4EKMT2ANPSR1
Cafenstrole SCHEMBL2372948 0.74 DPP4 (0.42) DPP4ALDH1A1KDM4EKMT2A
Cafenstrole SCHEMBL6440340 0.72 KDM4E (0.38) ALDH1A1KDM4EKMT2A
SCHEMBL9378261 0.72 DPP4 (0.36) DPP4ALDH1A1KDM4EKMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238720-B2 Pharmaceutical use of N-carbamoylazole derivatives EISAI R & D MANAGEMENT CO. LTD. (JP) 2007-07-03 US disclosed
US-7238720-B2 Pharmaceutical use of N-carbamoylazole derivatives EISAI R & D MANAGEMENT CO. LTD. (JP) 2007-07-03 US disclosed
US-7238720-B2 Pharmaceutical use of N-carbamoylazole derivatives EISAI R & D MANAGEMENT CO. LTD. (JP) 2007-07-03 US disclosed
EP-1258480-B1 Pharmaceutical use of N-Carbamoylazole derivatives EISAI CO LTD (JP) 2004-11-10 EP disclosed
EP-1258480-B1 Pharmaceutical use of N-Carbamoylazole derivatives EISAI CO LTD (JP) 2004-11-10 EP disclosed
US-20040186153-A1 Pharmaceutical use of N-carbamoylazole derivatives EISAI R & D MANAGEMENT CO. LTD. (JP) 2004-09-23 US disclosed
US-20030060494-A1 Pharmaceutical use of N-carbamoylazole derivatives EISAI CO., LTD. (JP) 2003-03-27 US disclosed
EP-1258480-A1 Pharmaceutical use of N-Carbamoylazole derivatives Eisai Co., Ltd. (JP) 2002-11-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186153-A1 Pharmaceutical use of N-carbamoylazole derivatives DPP4, DPP3, DPP7 DPP4 1/4885ALDH1A1 1026/4885MAPT 3669/4885
US-20030060494-A1 Pharmaceutical use of N-carbamoylazole derivatives DPP4, DPP3, DPP7 DPP4 1/4885ALDH1A1 1026/4885MAPT 3669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.